SOLUBLE ICAM-1 IN HODGKINS-DISEASE - A PROMISING INDEPENDENT PREDICTIVE MARKER FOR SURVIVAL

被引：26

作者：

CHRISTIANSEN, I ^{[1
]}

ENBLAD, G ^{[1
]}

KALKNER, KM ^{[1
]}

GIDLOF, C ^{[1
]}

GLIMELIUS, B ^{[1
]}

TOTTERMAN, TH ^{[1
]}

机构：

[1] UNIV UPPSALA HOSP,DEPT CLIN IMMUNOL & TRANSFUS MED,S-75185 UPPSALA,SWEDEN

来源：

LEUKEMIA & LYMPHOMA | 1995年 / 19卷 / 3-4期

关键词：

SOLUBLE ICAM-1; HODGKINS DISEASE; SURVIVAL; PREDICTIVE MARKER; MARKERS;

D O I：

10.3109/10428199509107894

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The serum levels of soluble ICAM-1 (sICAM-1, sCD54) were significantly elevated (p = .0006) in patients with Hodgkin's disease (HD) (n = 101) compared to healthy controls (n = 31). Serum levels of sICAM-1 in HD correlated significantly with the presence of B-symptoms, histology and tumour burden as reflected in the Ann Arbor staging system, but not to bulky disease. sICAM-1 was compared to other serum factors claimed to be of prognostic significance in HD, including erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH), deoxythymidine kinase (TK), soluble interleukin-2 receptor (sIL-2R, sCD25) and soluble CD30 (sCD30, sKi-1-antigen). Serum levels of sICAM-1 correlated positively with all of these markers. In univariate regression analyses, all but ESR correlated with disease-free survival but only sICAM-1, sIL-2R and sCD30 correlated with overall survival. In multivariate analyses only sIL-2R (as a continuous variable) added independent prognostic information in addition to age, stage and B-symptoms. sICAM-1 and sCD30 approached significance (p = 0.07 and p = 0.08, respectively) for disease-free survival. sCD30 correlated with overall survival (p = 0.03) while sICAM-1 did not. When dichotomised at optimal cut-off levels, sICAM-1 as well as sIL-2R and sCD30 added independent prognostic information for both disease-free acid overall survival. Based on the present observations, it appears that sICAM-1 may be a predictor for relapse and survival in HD, Determination of serum levels of sICAM-1 (in addition to sIL-2R and sCD30) may thus be of potential value when selecting HD patients eligible for intensive therapy in clinical trials.

引用

页码：243 / 251

页数：9

共 48 条

[1]

Bonadonna G., Valagussa P., Influence of clinical trials on current treatment strategy for Hodgkin's disease, Int. J. Radiat. Oncol. Biol. Phys., 19, pp. 209-218, (1990)

[2]

Urba W.J., Longo D.L., Hodgkin's disease, N. Engl. J. Med., 326, pp. 678-687, (1992)

[3]

Gobbi P.G., Cavalli C., Federico M., Lombardo M., Bertolini D., Grignani G.E., Pieresca C., Ascari E., Mauri C., Increasing interdependency of prognosis- and therapy-related factors in Hodgkin's disease, Acta Haemat, 81, pp. 34-40, (1989)

[4]

Proctor S.J., Taylor P.R.A., Classical staging of Hodgkin's disease is inappropriate for selecting patients for clinical trials of intensive therapy: the case for the objective use of prognostic factor information in addition to classical staging, Leukemia, 7, pp. 1911-1914, (1993)

[5]

Schilling R.F., McKnight B., Crowley J.J., Prognostic value of serum lactic dehydrogenase level in Hodgkin's disease, J. Lab. Clin Med., 99, pp. 382-387, (1982)

[6]

Loeffler M., Mauch P., Maclennan K., Specht L., Henry-Amar M., Workshop I: Review on prognostic factors, Ann. Oncol., 3, pp. 63-66, (1992)

[7]

Eriksson K., Hagberg H., Glimelius B., Sundstrom C., Gronowitz S., Kallander C., Serum thymidine kinase as a prognostic marker in Hodgkin's disease, Acta Radiol. Oncol., 2, pp. 167-171, (1985)

[8]

Pizzolo G., Vinante F., Chilosi M., Dallenbach R., Josimovic-Alasevic O., Diamantstein T., Stein H., Serum levels of soluble CD30 molecule (Ki-I antigen) in Hodgkin's disease: relationship with disease activity and clinical stage, Br. J. Haematol., 75, pp. 282-284, (1990)

[9]

Gause C., Pohl A., Tschiersch A., Da Costa L., Jung W., Diehl V., Hasenclever O., Pfreundschuh M., Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease, Blood, 77, pp. 1983-1988, (1991)

[10]

Ambrosetti A., Nadali G., Vinante F., Carlin S., Verneri D., Todeschini G., Morosato L., de Sabata D., Chilosi M., Maggi E., Parrochi P., Romagnani S., Sementzo G., Perona G., Pizzolo G., Serum levels of soluble interleukin-2 receptor in Hodgkin's disease, Cancer, 72, pp. 201-206, (1993)

← 1 2 3 4 5 →